Surveillance for possible immunological reactions after BCRO fetal precursor cell transplantation

Jump to: navigation, search

There are many published medical reports on hundreds of patients showing that changes of laboratory parameters of the immune system function after fetal precursor cell transplantation, using the pre-fetal cell transplantation levels as a baseline, are minimal and statistically not significant. 

According to U.S.FDA regulations the repeated implantation of cell transplants should greatly increase the risk of allergic and immunologic reactions, yet the clinical practice is refuting such expectations. Such requirements never existed in Europe where millions of patients have been treated by fetal cell xeno-transplantations, and repeatedly so, without any significant immune system reactions. In 264 patients who underwent between 1 and 12 cell therapy treatment antibody levels against sheep erythorocytes and organ specific antibodies against fetal sheep liver were measured. (The cell therapy preparations were prepared from sheep fetuses.) In 54 new patients that has never received zellentherapie, and thus served as a control group, antibodies against sheep erythrocytes and sheep fetal liver were found in more than one half. Titers of 1:32 were classified as non-specific and 1:64 as border-line. In only 11% of patients from the group that received between 1 and 7 cell therapy treatments there were significant titers of antibodies against sheep erythrocytes and sheep fetal liver in the range from 1:128 to 1:256, but clinically no significant reactions were observed. An immune tolerance through MALT and GALT or low immunogenicity of cell therapy preparations explain the observations. VI.BIBLIOGRAPHY [263]

If cell therapy preparations prepared without any special technology of primary tissue culture cause such minimal immunological reactions it is not surprising that when fetal precursor cell transplants have been prepared ‘lege artis’, such as by the method described in this text, there are no immune reactions whatsoever.  

Until we will learn what life is (and many philosophers believe that it will never happen and thus cannot explain many aspects of the function of the living body, we have to be satisfied with the fact that implantation of fetal precursor cell transplants prepared by the ‘state-of-art’ method does not cause any clinically apparent immune reactions. 

Cell transplantologist can prove this fact by getting the following battery of immunological tests a minimum of 48 hours before fetal cell transplantation, and after FCT once a month three times, and subsequently every 3 months until satisfied that there is no reaction:

i/ total lymphocytes

ii/ T-lymphocytes (CD3+)

iii/ T-helpers (CD4+)

iv/ T-suppressors (CD8+) and CD4/CD8

v/ NK (CD16)

vi/ B-lymphocytes (CD22 and CD19)

vii/ serum IGG, IGA, IGM

viii/ serum complement (CH50).

The use of immunosuppression has been one of the main reasons why the success rate of cell transplantation has been so low in the U.S. 

Long-term immunosuppression is not only dangerous to the patients, it is detrimental to fetal precursor cell transplants, because these are very young cells, enormously sensitive to any toxin, and immunosuppressants are highly toxic, indeed.